Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Jun O. Liu

Jun O. Liu

Department Affiliation: Primary: Pharmacology and Molecular Sciences; Secondary: Oncology
Degree: Ph.D., Massachusetts Institute of Technology
Rank: Professor
Telephone Number: 410-955-4619
Fax Number: 410-955-4520
E-mail address: joliu@jhu.edu
School of Medicine Address: Room 516 Hunterian Building, 725 N. Wolfe Street, Baltimore, MD 21205


Chemical biology, molecular and cellular biology, and translational medicine

Our primary research interest lies at the interface between chemistry, biology, and medicine.  We employ high-throughput screening to identify modulators of various cellular processes and pathways that have been implicated in human diseases from cancer to autoimmune diseases.  Once biologically active inhibitors are identified, they will serve both as probes of the biological processes of interest and as leads for the development of new drugs for treating human diseases.

Among the biological processes of interest are cancer cell growth and apoptosis, angiogenesis, calcium-dependent signaling pathways, eukaryotic transcription and translation.

  • Exploration of the existing drug space for novel pharmacological activities with translational potential.

Drug discovery and development is a time-consuming and costly process. To accelerate the process, we have assembled a library of existing drugs, known as the Johns Hopkins Drug Library (JHDL).  We have screened the JHDL in both target- and cell-based assays for novel pharmacological activities. To date, we and our collaborators have identified a number of known drugs that exhibited previously unknown activity. The most interesting hits discovered in our lab

             Table 1. Representative examples of new activity of known drugs

Liu Table 1













alone include: (1) Itraconazole, a widely used antifungal drug, was found to possess potent anti-angiogenic activity. Mechanistic deconvolution has revealed that itraconazole operates through a novel mechanism; it blocks endothelial cell cycle progression through the G1 phase of cell cycle via inhibition of mTOR and it also blocks cholesterol trafficking through the lysosome. We and others demonstrated that itraconazole inhibited angiogenesis and tumor xenografts in animal models, which paved the way for itraconazole to enter multiple Phase 2 human clinical studies. To date, itraconazole has shown efficacy in treating non-small cell lung cancer in combination with pemetrexed, metastatic and castration-resistant prostate cancer and basal cell carcinoma. (2) Nitroxoline, a urinary tract antibiotic, was found to inhibit angiogenesis through dual inhibition of the type 2 methionine aminopeptidase and SIRT1 and 2, which culminate in differentiation of endothelial cells. As nitroxoline has a unique distribution with the highest concentration found in the urinary tract, it has potential in the treatment of cancers of the urinary tract including bladder cancer. (3) Nelfinavir, an HIV protease inhibitor, was found to selectively inhibit HER2+ breast cancer cells. Follow-up studies revealed that nelfinavir is a novel type of HSP90 inhibitor, interacting with HSP90 at a site distinct from the binding sites of previously known HSP90 inhibitors. Nelfinavir and improved analogs have potential as new treatment of HER2+ breast cancer. (4) Clofazimine, an important component of the multidrug regimen for treating leprosy since the 1960s, was found to be a novel inhibitor of Kv1.3 channel, thereby blocking the activation of effector memory T cells implicated in a multitude of autoimmune diseases. In addition to the aforementioned hits, novel inhibitors of HIF-1, the hedgehog signaling pathway and the Hippo signaling pathway have also been identified from JHDL by our collaborators.

  • Learning From Nature--Natural products as probes of eukaryotic transcription and translation processes.

Natural products are an invaluable source of both molecular probes and drug leads, particularly anticancer and anti-infective drugs. Triptolide is a natural product isolated from the Thunder God Vine, whose extracts have been used in traditional Chinese medicine as immunosuppressive and anti-inflammatory remedies for centuries. It displays strong inhibition of all cancer cell lines tested to date, with a mean IC50 value in the low nanomolar range. Its molecular mechanism of action, however, remained elusive for decades. Using a top-down approach, we identified XPB, a subunit of the general transcription factor TFIIH, as a molecular target of triptolide. We are currently

Liu Figure 1











 

 

 

attempting to gain deeper understanding of the interaction between triptolide and XPB and the cascade of cellular effects as a consequence of binding of triptolide to XPB. We are also making novel analogs of triptolide to improve its pharmacological activity as leads for developing anticancer drugs. In addition to triptolide, we have also been working on a number of natural products, including pateamine A, lactamidomycin and mycalamide that inhibit eukaryotic translation and cancer cell growth.

  • Imitating Nature--Generation of natural product-inspired macrocyclic combinatorial libraries for the discovery of novel inhibitors of protein-protein interactions.

The macrocyclic natural products FK506 and rapamycin are approved immunosuppressive drugs with important biological activities.  Both have been shown to inhibit T cell activation, albeit with distinct mechanisms.  In addition, rapamycin has been shown to have strong anti-proliferative activity. FK506 and rapamycin share an extraordinary mode of action; they act by recruiting an abundant and ubiquitously expressed cellular protein, the prolyl cis-trans isomerase FKBP, and the binary complexes subsequently bind to and allosterically inhibit their target proteins calcineurin and mTOR, respectively. Structurally, FK506 and rapamycin share a similar FKBP-binding domain but differ in their effector domains. In FK506 and rapamycin, Nature has taught us that switching the effector domain of FK506 to that in rapamycin, it is possible to change the targets from calcienurin to mTOR. We asked the question of whether we can replace the effector domain of rapamycin with yet another structural scaffold to target other proteins in the human proteome. Thus, we designed and generated a library of new macrocycles containing the FKBP-binding

Liu Figure 2











 

 

 

 

 

 

domain of rapamycin, which are named rapafucins. It is hoped that the newly generated rapafucins will be able to target novel proteins in the human proteome, particularly protein-protein interactions.

Representative Publications:

  • Kishor, C., Arya, T., Teddi, R., Chen, X., Saddanapu, V., Marapaka, A.K., Gumpena, R., Ma, D., Liu, J.O., Addlagatta, A.  Identification, biochemical and structural evaluation of species-specific inhibitors against type I methionine aminopeptidases.  J. Med. Chem. 56:5295-5305, 2013. Pub Med Reference
     
  • Liu, C., Ma, H., Wu, J., Huang, Q., Liu, J.O., Yu, L.  Arginine68 is an essential residue for the C-terminal cleavage of human Atg8 family proteins.  BMC Cell Biol. 14:27, 2013. Pub Med Reference
     
  • Kong, X., Peng, B., Yang, Y., Zhang, P., Qin, B., Han, D., Wang, C., Dang, Y., Liu, J.O., Yu, L.  p53 represses transcription of RING finger LIM domain-binding protein RLIM through Sp1.  PLoS One 8, e62832, 2013. Pub Med Reference
     
  • Zhang, F., Bhat, S., Gabelli, S.B., Chen, X., Miller, M.S., Nacev, B.A., Cheng, Y.L., Meyers, D.J., Tenney, K., Shim, J.S., Crews, P., Amzel, L.M., Ma, D., Liu, J.O.  Pyridinylquinazolines selectively inhibit h uman methionine aminopeptidase-1 in cells.  J. Med. Chem. 56:3996-4016, 2013. Pub Med Reference
     
  • Fatokun, A.A., Liu, J.O., Dawson, V.L., Dawson, T.M.  Identification through high-throughput screening of 4;-methoxyflavone and 3',4'-dimethoxyflavone as novel neuroprotective inhibitors of parthanatos.  Br. J. Pharmacol. 169:1263-1278, 2013. Pub Med Reference
     
  • Rudin, C.M., Brahmer, J.R., Juergens, R.A., Hann, C.L., Ettinger, D.S., Sebree, R., Smith, R., Aftab, B.T., Huang, P., Liu, J.O.  Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.  J. Thorac. Oncol. 8:619-623, 2013. Pub Med Reference
     
  • Bhat, S., Shim, J.S., Liu, J.O.  Tricyclic thiazoles are a new class of angiogenesis inhibitors.  Bioorg. Med. Chem. Lett. 23:2733-2737, 2013. Pub Med Reference
     
  • Zhang, P., Yang, X., Zhang, F., Gabelli, S.B., Wang, R., Zhang, Y ., Bhat, S., Chen, X., Furlani, M., Amzel, L.M., Liu, J.O., Ma, D.  Pyridinylpyrimidines selectively inhibit human methionine aminopeptidase-1.  Bioorg. Med. Chem. 21:2600-2617, 2013. Pub Med Reference
     
  • Wissing, M.D., Mendonca, J., Kim, E., Shim, J.S., Kaelber, N.S., Kant, H., Hammers, H., Commes, T., Van Diest, P.J., Liu, J.O., Kachhap, S.K.  Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells.  Cancer Biol. Ther. 14:401-410, 2013. Pub Med Reference
     
  • Choi, S.M., Kim, Y., Shim, J.S., Park, J.T., Wang, R.H., Leach, S.D., Liu, J.O., Deng, C.X., Ye, Z., Jang, Y.Y.  Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells.  Hepatology 57:2458-2468, 2013. Pub Med Reference
     
  • Kamiyama, H., Rauenzahn, S., Shim, J.S., Karikari, C.A., Feldmann, G., Hua, L., Kamiyama, M., Schuler, F.W., Lin, M.T., Beaty, R.M., Karanam, B., Liang, H., Mullendore, M.E., Mo, G., Hidalgo, M., Jaffee, E., Hruban, R.H., Jinnah, H.A., Roden, R.B., Jimeno, A., Liu, J.O., Maitra, A., Eshleman, J.R.  Personalized chemotherapy profiling using cancer cell lines from selectable mice.  Clin. Cancer Res. 19:1139-1146, 2013. Pub Med Reference
     
  • Kurata, S., Shen, B., Liu, J.O., Takeuchi, N., Kaji, A., Kaji, H.  Possible steps of complete disassembly of post-termination complex by yeast eEF3 deduced from inhibition by translocation inhibitors.  Nucleic Acids Res. 41:264-276, 2013. Pub Med Reference
     
  • Yang, Y., Wang, C., Zhang, P., Gao, K., Wang, D., Yu, H., Zhang, T., Jiang, S., Hexige, S., Hong, Z., Yasui, A., Liu, J.O., Huang, H., Yu, L.  Polycomb group protein PHF1 regulates p53-dependent cell growth arrest and apoptosis.  J. Biol. Chem. 288:529-539, 2013. Pub Med Reference
     
  • Shim, J.S., Rao, R., Beebe, K., Neckers, L., Han, I., Nahta, R., Liu, J.O.  Selective inhibition of Her2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.  J. Natl. Cancer Inst. 104:1576-1590, 2012. Pub Med Reference
     
  • Chen, X.Y., Gu, X.T., Saiyin, H., Wan, B., Zhang, Y.J. Li, J. Wang, Y.L, Gao, R., Wang, Y.F., Dong, W.P., Najjar, S.M., Zhang, C.Y., Ding, H.F., Liu, J.O., Yu, L.  Brain-selective kinase 2 (BRSK2) phosphorylation on PCTAIRE1 negatively regulates glucose-stimulated insulin in pancreatic ß-cells.  J. Biol. Chem. 287:30368-30375, 2012. Pub Med Reference
     
  • Krátký, M., Vinšová, J., Novotná, E., Mandiková, J., Wsól, V., Trejtnar, F., Ulmann, V., Stolařiková, J, Fernandes, S., Bhat, S., Liu, J.O.  Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase.  Tuberculosis 92:434-439, 2012.  Pub Med Reference
     
  • Liu-Chittenden, Y., Huang, B., Shim, J.S., Chen, Q., Lee, S.J., Anders, R.A., Liu, J.O., Pan, D.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.  Genes Dev. 26:1300-1305, 2012. Pub Med Reference
     
  • Bhat, S., Olaleye, O., Meyer, K.J., Shi, W., Zhang, Y., Liu, J.O.  Analogs of N'-hydroxy-N-(4H, 5H-naphtho[1,2-d]thiazol-2-yl)methanimidamide inhibit Mycobacterium tuberculosis methionin aminopeptidases.  Bioorg. Med. Chem. 20:4507-4513, 2012. Pub Med Reference
     
  • Bhat, S., Shim, J.S., Zhang, F., Chong, C.R., Liu, J.O.  Substituted oxines inhibit endothelial cell proliferation and angiogenesis.  Org. Biomol. Chem. 10:2979-2992. 2012. Pub Med Reference
     
  • Wang, C., An, J., Zhang, P., Xu, C., Gao, K., Wu, D., Wang, D., Yu, H., Liu, J.O., Yu, L.  The Nedd4-like ubiquitin E3 ligases target angiomotin/p130 to ubiquitin-dependent degradation.  Biochem. J. 444:279-289, 2012. Pub Med Reference
     
  • Titov, D.V., Liu, J.O.  Identification and validation of protein targets of bioactive small molecules.  Bioorg. Med. Chem. 20:1902-1909, 2012. Pub Med Reference
     
  • Xing, S., Bhat, S., Shroff, N.S., Zhang, H., Lopez, J.A., Margolick, J.B., Liu, J.O., Siliciano, R.F.  Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+T cell model withough inducing global T cell activation.  J. Antimicrob. Chemother. 67, 398-403, 2012. Pub Med Reference
     
  • Olaleye, O., Raghunand, T.R., Bhat, S., Chong, C., Gu, P., Zhou, J., Zhang, Y., Bishai, W.R., Liu, J.O.  Characterization of clioquinol and analogues as novel inhibitors of methionine aminopeptidases from Mycobacterium tuberculosis.  Tuberculosis Suppl 1, S61-65, 2011. Pub Med Reference
     
  • Peng, C.C., Shi, W., Lutz, J.D., Kunze, K.L., Liu, J.O., Nelson, W.L., Isoherranen, N.  Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.  Drug Metab. Dispos. 40: 426-435, 2011. Pub Med Reference
     
  • Rovira, M., Huang, W., Yusuff, S., Shim, J.S., Ferrante, A.A., Liu, J.O., Parsons, M.J.  Chemical screen identifies FDA-approved drugs and target pathways that induce precocious pancreatic endocrine differentiation.  Proc. Natl. Acad. Sci. USA 108:19264-19269, 2011. Pub Med Reference
     
  • Nacev, B.A., Grassi, P., Dell, A., Haslan, S.M., Liu, J.O.  The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking and signaling in endothelial cells.  J. Biol. Chem. 286:44045-44056, 2011. Pub Med Reference
     
  • Chamni, S., He, Q.L., Dang, Y., Bhat, S., Liu, J.O., Romo, D.  Diazo reagents with small steric footprints for simultaneous arming/SAR studies of alcohol-containing natrual products via O-H insertion.  ACS Chem. Biol. 6:1175-1181, 2011. Pub Med Reference
     
  • Aftab, B.T., Dobromilskaya, I., Liu, J.O., Rudin, C.M.  Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer.  Cancer Res. 71:6764-6772, 2011. Pub Med Reference
     
  • Nacev, B.A., Liu, J.O.  Synergistic inhibition of endothelial cell proliferation, tube formation, and sprouting by cyclosporine A and itraconazole.  PLoS One 6, e24793, 2011. Pub Med Reference
  •  
  • Shi, W., Nacev, B.A., Aftab, B.T., Rudin, C.M., Liu, J.O.  Itraconazole side chain analogues: Structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGF2) glycosylation, and hedgehog signaling.  Med. Chem. 54:7363-37374, 2011. Pub Med Reference
  • Li, W., Bhat, S., Liu, J.O.  A simple and efficient route to the FKBP-binding domain from rapamycin.  Tetrahedron Lett. 52:5070-5072, 2011. Pub Med Reference
  • Dang, Y., Schneider-Poetsch, T., Eyler, D.E., Jewett, J.C., Bhat, S., Rawal, V.H., Green, R., Liu, J.O.  Inhibition of eukaryotic translation elongation byt the antitumor natural product Mycalamide B.  RNA 17:1578-1588, 2011. Pub Med Reference

  • Nacev, B., Low, W.K., Huang, Z., Su, T., Su, Z., Alkuraya, H., Kasuga, D., Sun, W., Tranger, M., Braun, M., Fischer, G., Zhang, K., Liu, J.O.  A calcineurin-independent mechanism of angiogenesis inhibition by a non-immunosupporessive cyclosporin A analog.  J. Pharmacol. Exp. Ther. 338:466-475, 2011. Pub Med Reference

  • Platz, E.A., Yegnasubramanian, S., Liu, J.O., Chong, C.R., Shim, J.S., Kenfield, S.A., Stampfer, M.J., Willett, W.C., Giovannucci, E., Nelson, W.G.  A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prastate cancer treatment.  Cancer Discovery 1:68-77, 2011. Pub Med Reference
  • Wilson, B.A., Wang, H., Nacev, B.A., Mease, R.C., Liu, J.O., Pomper, M.G., Isaacs, W.B.  High-throughput screen identifies novel inhibitiors of cancer biomarker amethyacyl coenzyme A rasemase (AMACR/P504S).  Mol. Cancer Ther. 10:825-838, 2011. Pub Med Reference
  • Titov, D.V., Gilman, B., He, Q., Bhat, S., Low, W.K., Dang, Y., Smeaton, M., Demain, A.L., Miller, P.S., Kugel, J.F., Goodrich, J.A., Liu, J.O.  XPB, a subunit of TFIIH, is a target of the natural product triptolide.  Nat. Chem. Biol. 7:182-188, 2011.  Pub Med Reference
  • He, J., Ye, J., Cai, Y., Riquelme, C., Liu, J.O., Liu, X., Han, A., Chen, L.  Structure of p300 bound to MEF2 on DNA reveals a mechanism of enhanceosome assembly.  Nucleic Acids Res. 39:4464-4474, 2011. Pub Med Reference
  • Liu, J.O., Titov, D.V., Dang, Y., He, Q.  Regulator of ras depalmitoylation and retrograde trafficking: a new hat for FKBP.  Mol. Cell 41:131-133, 2011. Pub Med Reference
  • Shim, J.S., Matsui, Y., Bhat, S., Nacev, B.A., Xu, H., Bhang, H.E., Dhara, S., Han, K.C., Chong, C.R., Pomper, M.G., So, A., Liu, J.O.  Effect of nitroxolibne on angiogenesis and growth of human bladder cancer. J. Natl. Cancer Instl. 102:1855-1873, 2010. Pub Med Reference
  • Lin, J., Haffner, M.C., Zhang, Y., Lee, B.H., Brennen, W.N., Britton, J., Kachhap, S.K., Shim, J.S., Liu, J.O., Nelson, W.G., Yegnasubramanian, S., Carducci, M.A.  Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.  Prostate 71:333-343, 2010. Pub Med Reference
  • Zhu, P., Jiang, W., Cao., L., Yu, W., Pei, Y., Yang, X., Wan, B., Liu, J.O., Yi, Q., Yu, L.  IL-2 mRNA stabilization upon PMA stimulation is dependent on NF90-Ser647 phosphorylation by protein kinase CbI.  J. Immunol. 185:5140-5149, 2010. Pub Med Reference
  • Huang, W., Ding, L., Huang, Q., Hu, H., Liu, S., Yang, X., Hu, X., Dang, Y., Shen, S., Li, J., Ji, X., Jiang, S., Liu, J.O., Yu, L.  Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma.  Hepatology 52:703-714, 2010. Pub Med Reference
  • Xiao, Q., Zhang, F., Nacev, B.A., Liu, J.O., and Pei, D.  Protein N-terminal processing: substrate specificity of Escherichia coli and human methionine aminopeptidases.  Biochemistry 49:5588-5599, 2010. Pub Med Reference
  • Shi, W., Nacev, B.A., Bhat, S., Liu, J.O.  Impact of absolute stereochemistry on the antiangiogenic and antifungal activities of itraconazole.  ACS Med. Chem. Lett. 1:155-159, 2010. Pub Med References
  • Li, W., Dang, Y., Liu, J.O., and Yu, B.  Structural and stereochemical requirements of the spiroketal group of hippuristanol for antiproliferative activity.  Bioorg. Med. Chem. Lett. 20:3112-3115, 2010. Pub Med Reference
  • Kim, J., Tang, J.Y., Gong, R., Kim, J., Lee, J.J., Clemons, K.V., Chong, C.R., Chang, K.S., Fereshte, M., Gardner, D., Reya, T., Liu, J.O., Epstein, E.H., Stevens, D.A., Beachy, P.A. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth.  Cancer Cell 17:388-399, 2010. Pub Med Reference
  • Xu, J., Dang, Y., Ren, Y.R., Liu, J.O.  Cholesterol trafficking is required for mTOR activation in endothelial cells.  Proc. Natl. Acad. Sci. USA 107:4764-4769. 2010. Pub Med Reference
  • Schneider-Poetsch, T., Ju, J., Eyler, D.E., Dang, Y., Bhat, S., Merrick, W.C., Green, R., Liu, J.O.  Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin.  Nat. Chem. Biol. 6:209-217, 2010. Pub Med Reference
     
  • Olaleye, O.A., Taghunand, R.R., Bhat, S., He, J., Tyagi, S., Lamichhane, G., Gu, P., Zhou, J., Zhang, Y., Grosset, J., Bishai, W.R., Liu, J.O.  Methionin aminopeptidases from Mycobacterium tuberculosis as novel antimycobacterial targets. Chem. Biol. 17:86-97, 2010. Pub Med Reference
  • Zhang, P., Wang, C., Gao, K., Wang, D., Mao, J., An, J., Xu, C., Wu, D., Yu, H., Liu, J.O., Yu, L.  The ubiquitin ligase itch regulates apoptosis by targeting thioredocin-interacting protein for ubiquitin-dependent degradation.  J. Biol. Chem. 285:8869-8879, 2010. Pub Med Reference
  • Yang, H.C., Xing, S., Shan, L., O'Connell, K., Dinoso, J., Shen, A., Zhou, Y., Shrum, C.K., Han, Y., Liu, J.O., Zhang, H., Margolick, J.B., Siliciano, R.F.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.  J. Clinic. Invest. 119:3473-3489, 2009. Pub Med Reference
  • Lee, K., Zhang, H., Qian, D.Z., Rey, S., Liu, J.O., Semenza, G.L.  Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization.  Proc. Natl. Acad. Sci. USA 106:17910-17915, 2009. Pub Med Reference
     
  • Li, W., Dang, Y., Liu, J.O., Yu, B.  Expeditious Synthesis of Hippuristanol and Congeners with Potent Antiproliferative Activities.  Chemistry, Eur. J.  15:10356-10359, 2009. Pub Med Reference
  • Pan, F., Yu, H., Dang, E.V., Barbi, J., Pan, X., Grosso, J.F., Jinasena, D., Sharma, S.M., McCadden, E.M., Getnet, D., Drake, C.G., Liu, J.O., Ostrowski, M.C., Pardoll, D.M.  Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells.  Science 325:1142-1146, 2009. Pub Med Reference
  • Woodard, L.E., Chang, W., Chen, X., Liu, J.O., Shapiro, T.A., Posner, G.H.  Malaria-Infected Mice Live until at Least Day 30 after a New Monomeric Trioxane Combined with Mefloquine Are Administered Together in a Single Low Oral Dose.  J. Med. Chem. 52:7458-7462, 2009. Pub Med Reference
     
  • Dang, Y., Low, W.K., Xu, J., Gehring. N. H., Dietz, H.C., Romo, D., Liu, J.O.  Inhibition of nonsense-mediated mRNA decay by the natural product pateamine A through eukaryotic initiation factor 4AIII.  J. Biol. Chem. 284: 23613-23621, 2009.  Pub Med Reference
     
  • Zhang, Y., Byun, Y., Ren, Y.R., Liu, J. O., Laterra, J., Pomper, M.G.  Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay. Cancer Res. 69:5867-5875, 2009. Pub Med Reference
     
  • Liu, J.O., Nacev, B.A., Xu, J., Bhat, S.  It takes two binding sites for calcineurin and NFAT to tango.  Mol. Cell 33: 676-678, 2009. Pub Med Reference
     
  • Rosenthal, A.S., Chen, X., Liu, J.O., West, D.C., Hergenrother, P.J., Shapiro, T.A., Posner, G.H.  Malaria-Infected Mice Are Cured by a Single Oral Dose of New Dimeric Trioxane Sulfones Which Are Also Selectively and Powerfully Cytotoxic to Cancer Cells.  J. Med. Chem 52:1198-1203, 2009. Pub Med Reference
     
  • Liu, J.O.  Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation.  Immunol. Rev. 228:184-198, 2009. Pub Med Reference
     
  • Chen, X., Xie, S., Bhat, S., Kumar, N., Shapiro, T.A., Liu, J.O.  Fumagillin and fumarranol interact with P. falciparum methionine aminopeptidase 2 and inhibit malaria parasite growth in vitro and in vivoChem. Biol. 16:193-202, 2009. Pub Med Reference
  • Lee, K., Qian, D.Z., Rey, S., Wei, H., Liu, J.O., Semenza, G.L.  Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells.  Proc. Natl. Acad. Sci. USA 106:2353-2358, 2009. Pub Med Reference

Other graduate programs in which Dr. Liu participates:

BCMB Program
Chemistry-Biology Interface Program (CBI)

 
 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer